Analysis
Ebola virus disease has a high case‑fatality rate (up to 90% in past outbreaks) and is recognized as one of the world’s most lethal infectious diseases. The DRC’s eastern provinces face ongoing conflict, displacement, and weak health infrastructure, making them among the most hazardous settings for outbreak control. By mid‑2019, the rVSV‑ZEBOV vaccine (Ervebo) had been licensed and was being deployed, and rapid diagnostic tests and monoclonal‑antibody treatments (e.g., REGN‑EB3) were available, representing significant advances over earlier responses.
Background
The 10th Ebola outbreak in the DRC began in August 2018 and continued into 2019, with over 3,000 cases reported. The WHO and partners highlighted security challenges and community mistrust that hampered containment. In 2019, WHO approved the first Ebola vaccine, and several experimental therapeutics were used under compassionate protocols, marking a new era of tools for Ebola control.
Verdict summary
The statement accurately describes Ebola as a highly dangerous disease in a challenging region, while noting that new tools such as vaccines and diagnostics improve response.